Sign inJoin
Company / Finance

Vertex Pharmaceuticals Incorporated

VRTX · NASDAQ

Vertex reported FY2025 revenue of $12.00 billion and Q1 2026 revenue of $2.99 billion, with the official record tying the thesis to cystic-fibrosis durability, pipeline diversification, cash conversion and R&D execution.

FollowAdd to WatchlistAsk Question
NASDAQVRTXCoverage BootstrapVertex Pharmaceuticals Incorporated
Latest ReportMay 19, 2026Vertex: the CF cash engine still has to prove the next pipeline legView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 of 1 reports match
Clear filters
Selected tags
Nasdaq
Clear tags
Latest Thesis

Vertex: the CF cash engine still has to prove the next pipeline leg

Vertex reported FY2025 revenue of $12.00 billion and Q1 2026 revenue of $2.99 billion, with the official record tying the thesis to cystic-fibrosis durability, pipeline diversification, cash conversion and R&D execution.

May 19, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Vertex Pharmaceuticals Incorporatedthe CF cash engine still has to prove the next pipeline legMay 19, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Vertex: the CF cash engine still has to prove the next pipeline legVertex reported FY2025 revenue of $12.00 billion and Q1 2026 revenue of $2.99 billion, with the official record tying the thesis to cystic-fibrosis durability, pipeline diversification, cash conversion and R&D execution.NASDAQMay 19, 2026Research reportReadSlides